Infographic: System data processing with TRACKMAN® Connected
Learn how Gilson has built a secure platform for our TRACKMAN® Connected based on technology and industry best practices.
List view / Grid view
Learn how Gilson has built a secure platform for our TRACKMAN® Connected based on technology and industry best practices.
Improve the traceability of your research by following these 10 simple steps for using Gilson’s connected products at the bench.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
A study has revealed that the compound cannabigerol (CBG) is effective as an antibacterial in mice, by preventing bacteria from forming biofilms.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
25 February 2020 | By Bruker Daltonics
Learn about the latest software tools for Bruker Daltonic’s SPR instrumentation and explore high-throughput screening strategies enabled by their ecosystem.
Upregulating utrophin using small molecules could be a new therapeutic approach for Duchenne muscular dystrophy (DMD).
A new method has been developed by researchers to create synthetic molecules which replicate natural structures and have potential medicinal uses.
Backgrounded Membrane Imaging (BMI), used by the HORIZON® particle analysis system, performs measurements of subvisible protein aggregates.
Are you missing the bigger picture with your AAV analytics? Subvisible particle analysis should not require millilitres of precious sample.
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
Various potential therapeutic opportunities to treat spinocerebellar ataxia type 7 (SCA7) have been discovered in a new study into the neurodegenerative disorder.
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s Discovery Director Dr Charles Mowbray to hear how the organisation is working to identify new leads with activity in animal models of neglected tropical diseases and the potential for further…